Raymond James analyst C. Gregory Peters raised the firm’s price target on HealthEquity (HQY) to $120 from $115 and keeps a Strong Buy rating on the shares. HealthEquity’s management made considerable progress in Q1 on addressing the fraud activity that plagued the company in the last three quarters, the analyst tells investors in a research note. The firm expects HealthEquity to deliver double digit free cash flow and earnings growth with additional margin expansion through fiscal 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- Buy Rating for HealthEquity: Legislative Developments and Market Growth Potential
- Healthequity Announces New $300 Million Stock Buyback
- Buy Rating for Healthequity Amid Legislative Opportunities and Market Expansion Potential
- HealthEquity price target raised to $125 from $112 at Barrington
- HealthEquity’s Strong Financial Performance and Optimistic Guidance Justify Buy Rating and Increased Price Target